FDA Advisory No.2024-0498 || Delisting of COVID-19 Medicines and Devices from the List of VAT-Exempt Health Products
Republic Act (RA) No. 11534 known as the “Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act” provided Value-Added Tax (VAT) Exemption to certain health products including, Drugs for Hypertension, […]
FDA Advisory No.2024-0473 || Suspension of Customer Relation Management Information System (CRMIS) starting 01 March 2024
The Food and Drug Administration hereby notifies the general public of the suspension of the FDA Customer Relation Management Information System (FDA-CRMIS) which was implemented through the issuance of FDA […]
FDA Advisory No.2024-0329 || Endorsement of Updates on the List of VAT-Exempt Medicines
Section 12 of Republic Act (RA) No. 11534 known as the “Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act” provided Value-Added Tax (VAT) Exemption to certain health products including, […]
FDA Advisory No.2024-0320 || AD INTERIM AVAILABILITY OF OVER-THE-COUNTER (OTC) PAYMENT FOR SELECTED FDA APPLICATIONS/ TRANSACTIONS
In the interest of effective delivery of public service, the Food and Drug Administration (FDA) would like to inform all FDA stakeholders of the availability of Over-the-Counter (OTC) Payment System […]
Joint Advisory of DA-BFAR and FDA || All Exporters of Fish and Fishery/ Aquatic Products and Processed Meat and Meat Products to Kingdom of Saudi Arabia
https://www.sfda.gov.sa/en/forms/79005 Attachments JOINT ADVISORY OF DA-BFAR AND FDA (373 kB)
FDA Advisory No.2024-0006 || Endorsement of Updates on the List of VAT-Exempt Health Products
Section 12 of Republic Act (RA) No. 11534 known as the “Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act” provided Value-Added Tax (VAT) Exemption to certain health products including, […]
FDA Advisory No.2023-2539 || Pilot Implementation of the Food and Drug Administration eServices Portal System for License to Operate Application of Food Manufacturers within National Capital Region
The Food and Drug Administration (FDA) continues its digital system enhancement through the development of online application platforms including the eServices Portal System. This intends to simplify the process of […]
FDA Advisory No.2023-2538 || Common Services Laboratory (CSL) Submission Holiday
To ensure continuous improvement of its services, the CSL will conduct its inventory of pending requests for analysis and regular equipment system maintenance starting 27 December 2023 until 12 January […]
FDA Advisory No.2023-2534 || End of Pilot Implementation of the Food and Drug Administration eServices Portal System for License to Operate Application of Drug Manufacturers from the Selected Regions
The Food and Drug Administration hereby notify the general public and all drug manufacturers, packers, and repackers from the following regions that the pilot implementation for License to Operate application […]
FDA Advisory No.2023-2401 || COMMON SERVICES LABORATORY CY 2023 YEAR-END PROGRAM IMPLEMENTATION REVIEW (PIR)
To assess the performance of the laboratory against the predetermined objectives and benchmarks, thereby providing insights into the laboratory’s intended outcomes and identifying areas for improvement for seamless processes, all […]